Cited 0 times in
Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.